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Dear Rector Magnificus, dear colleagues, dear friends and family,
Toxicology has been a part of human society long before there was a written history. 
It is not too difficult to imagine that human beings in search of food will have 
encountered occasional intoxications. Evidence of the use of herbs and plants for 
medical purposes has been found in nearly all cultures, with or without a written 
history. In fact throughout the ages, those who practiced the use of natural medicine 
have generally taken a relatively high place in any society. Knowledge about 
beneficial and toxicological effects of naturally occurring substances (most likely 
complex mixtures) must have first been obtained from human practice. Without 
the advantages of the written word, such knowledge has been passed from one 
generation to the other by oral narrative.
I think most of us are also aware that this knowledge of toxins has also been put 
into practice for good and for bad and even for political purposes. For instance, 
the philosopher Socrates was put to death by forcing him to drink a cup of poison 
hemlock extract in the year 399 BC. For those who are interested; the most noted of 
hemlock toxins is Coniine. Coniine disrupts the functioning of the central nervous 
system by blocking the neural signals to the muscles in a manner similar to the 
Amazonian dart poison curare. This results in an ascending muscular paralysis 
which eventually affects the respiratory muscles causing death by suffocation. 
Where there is bad, there usually also must be good. Venom based cures are 
mentioned in Sanskrit text in the second century B.C. and Mithradates VI of Pontus 
was known to use an anti-dote which supposedly saved his life twice on the battle 
filed. This anit-dote known as Mithridate, contains as many as 65 ingredients. It was 
among one of the most complex, highly sought-after drugs during the Middle Age 
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and Renaissance. Legend has it that Mithradates fortified his body against poisons 
to such an extent that when he tried to kill himself, he could not find any poison that 
would have an effect. After loosing the final battle against Rome, the recipe of it was 
found in his cabinet and was carried to Rome.
More recently some cases of intentional human poisoning have been recorded that 
would have suited a James Bond movie. In 1978, Georgi Markow, a Bulgarian 
dissident writer, was pinched in his thigh, presumably by a needle hidden in an 
umbrella, in London. He noticed a small red welt had formed at the site of the sting. 
That evening he developed a fever and was admitted to a hospital where he died 
three days later. The cause of death was poisoning from a ricin-filled pellet. In 2006 
Alexander Litvinenko, an ex-officer of the KGB, went to hospital complaining of 
signs of poisoning. In the next days his health deteriorated rapidly. Initially it was 
thought to be a case of Thallium poisoning, urine samples only a few hours before 
he died demonstrated great quantities of radioactive Polonium-210 in a London 
hospital. Apparently, London is a dangerous place to live.
On the other hand, not all attempted poisonings are successful. For example, the 
attempted assassination of Ukrainan president Viktor Yushchenko with TCDD is 
quite revealing. This case is interesting because it demonstrates a misinterpretation 
of the toxicological data from animal studies. In the popular press, TCDD (the most 
potent of the dioxins) is often referred to as a mega poison. TCDD indeed has a 
significant toxicological potential, but in terms of lethality, it is far less deadly to 
humans than guinea-pigs. Victor Yushchenko survived the attack on his life 
although the characteristic acute effect of dioxin poisoning, chloroacne, affected his 
appearance. (Details of the above mentioned cases were obtained from Wikipedia).
The first documented animal experiments to detect toxic effects also date back to 
Greek times. Aristotle was amongst the first who performed and reported on in vivo 
animal experiments. In this context I will be using the word “in vivo” for studies 
involving animals and “in vitro” for studies involving cell based systems; such 
studies are also referred to as replacement or alternative testing methods. 
Considering that humans have existed as a species for more than 200,000 years, it 
can be said that we have survived reasonably well without animal studies for 
more than 99% of our “species time”. The number of animal studies, however, 
has gradually increased in the last century. In fact, there is a positive correlation 
between the number of animal studies and the gross social product of a country 
(see figure 1).
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Figure 1. Correlation between the number of animal studies performed in a country and its gross 
domestic product (GDP)
In the previous century new chemicals were developed at high speed as a result of 
the industrial revolution and scientific progress, particularly for pharmaceuticals, 
and these chemicals were often put on the market without much toxicity testing. It 
should thus come as no surprise that the history of economical development and 
toxicology has been anything but smooth. There are a number of well-known cases 
were previous knowledge of the toxicological potential of compounds would have 
prevented human and environmental disaster. We only need to think about the 
effects of DDT and Thalidomide, to understand why the catalogue of studies that 
need to be performed has grown (which each disaster) over the years. At the same 
time, ethical concerns for animal welfare have also been rising, necessitating the 
development of alternatives to animal studies.
The first (and still one of the best) of these alternative approaches to animal research 
were proposed by Russell and Burch in 1956 (Russel and Burch, 1956). They 
described a concept generally referred to as the 3Rs: Reduction, Refinement and 
Replacement. The beauty of this concept is that it approaches alternatives to animal 
testing not only from the replacement point of view (i.e. in vitro only), but also 
encourages other methodologies. Among these is reduction, the idea that studies can 
and should be done with the least number of animals necessary. Similarly, I believe 
that the concept of reduction also means that the number of animal studies 
performed during product development should be limited to the minimal number 
required to do proper hazard identification and risk assessment. I will get back to 
this point little later. 
Refinement was originally intended to indicate any new in vivo type of study using 
methods that would be less harmful or stressful for the animals. One example of a 
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successful refinement is the development of the mouse local lymph node assay 
(LLNA), in which the test substance is applied to the ears of a mouse, as an 
alternative to the maximization test, where it is injected under the skin of guinea-pigs 
(OECD test guideline 429). I propose to extend the concept of refinement to also 
include methods which have recently become available and provide a wealth of new 
data without the need to do additional animal studies. These new methods are often 
referred to as ‘omics sciences and consist of transcriptomics (the study of gene 
expression, by measuring messenger RNA), proteomics (the quantitative deter-
mination of proteins in organs and tissues) and metabolomics (the quantitative 
determination of naturally occurring small molecules in the body (see figure 2). 
‘Omics data can be obtained from any animal study and provide a (sometimes 
overwhelming) wealth of information. Thus, these ‘omics data now allow for an 
insight into the modes of action of a substance and thus for a better interpretation of 
the animal study. I believe that with this improved information situation we will be 
able to do fewer studies, each using fewer animals. I refer to this concept as “reduc-
tion through refinement”. Again I will give an example of this concept a little later.
Figure 2. The science of ‘omics is the study of a complete suite of biomolecules
So now let’s take a closer look at replacement, i.e. in vitro studies, now. The first, and 
considered by many to be the main advantage of in vitro studies is the reduction of 
animal testing . This ethical aspect is continuing to increase in importance; as 
exemplified by the fact that the Netherlands has a political party called “Party for the 
Animals” (partij voor de dieren) or by the fact that the German constitution was 
amended in 2002 to include provisions for animal welfare. 
A second often mentioned advantage is that in vitro studies are better suited for a 
targeted approach, or to address very specific questions which are often far more 
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difficult to address in an in vivo study. While this is true, this advantage turns into a 
disadvantage when we look at the fundamental question toxicologist are trying to 
address from a holistic point of view. There are two aspects which determine the 
toxicity (hazard) of a compound. (1) The toxicodynamics, that is what the chemical 
does with the body. This is the part that sometimes can be better studied in vitro. (2) 
The toxicokinetics, that is what the body does with the chemical. This part of the 
equation is often not included in in vitro models. What the substance does to the 
body is also referred to as ADME (absorption, distribution, metabolism and 
excretion). Therefore, if we go for replacement of animal studies by in vitro studies 
we must also address the kinetics. In my engagement here in Wageningen we will 
indeed look at both parts of this equation. Here in Wageningen we are developing 
mathematical computer models, based on biological evidence, which translate in vitro 
concentrations into in vivo values. Without such models it will be very difficult to use 
the results of in vitro testing beyond a simple yes or no answer. And yes or no is not 
enough to perform the necessary risk assessments in toxicology. Therefore I believe 
that the research work here at Wageningen University will be an essential tool in the 
enhancement of scientifically sound replacement of animal studies, and I am proud 
to be part of that effort. 
A third advantage of in vitro studies is that they use less test substance. This may 
sound somewhat trivial, but is, in my opinion, currently by far the largest advantage 
of in vitro studies. Why? Larger amounts (in the Kg range) of totally new chemicals 
and in particular (pharmaceutically) active ingredients usually are only produced in 
later stages of product development (following scale up of synthesis). The greatest 
misuse of both financial and animal resources is related to projects which fail during 
late stages of development. Here, I am particularly thinking about the development 
of new active ingredients for pharmaceutical and agrochemical products. In both 
cases, development costs far exceed 100 million euros and use up to 4000 animals, 
with rats making up the largest portion. Imagine if all this money, and all those 
animal lives were spent for nothing because during the last stages of development 
unacceptable effects are observed. Let me be clear, one of the most important roles 
that a toxicologist has in society is to ensure that disasters, like those seen with DDT 
or thalidomide, are prevented. In the past we may have been over-optimistic, you 
may even say careless, about the advantages of some pharmaceutical products 
without taking a closer look at their risks (see figure 3). So we need good regulation 
and we need good, reliable and relevant toxicological studies. 
However, there is also a risk that we use all of the aforementioned resources, and 
erroneously conclude that there is a serious risk and subsequently stop the devel-
opment of a very valuable product to society because of toxicological findings. I have 
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no doubt that aspirin would not have been developed by pharmaceutical companies 
if its toxicological potential would have been evaluated according to the methods and 
paradigms that we use today. Aspirin, sometimes referred to as the 8th wonder of 
the world, would not have made it to the market because it causes malformations in 
developmental rat studies, and few companies if any today, would have dared to try 
and market such a product.
Figure 3. Asprin, the 8th wonder of the world, together with what would now be perceived 
as inappropriate 19th century adverting of an illicit product
So what has this all got to do with the advantages of in vitro toxicology? It’s simple. 
We would like to know as much as we can about a new compound, as soon as 
possible. However, even a relatively small in vivo study, such as a 28-day toxicity 
study in rats, may require up to 200 g of test substance. Furthermore, at this stage of 
early development, companies are usually not only working with a single 
compound, but with many sharing a particular desired effect. It is not possible to 
synthesize 200g of material (which costs more than its weight in gold) for so many 
chemicals, to see it being devoured by rats within a month – only for one single test. 
So what is the solution? Behind all (severe) toxicological effects there is a mechanism, 
a mode of action. If we can develop the appropriate in vitro test, this would allow us 
to identify these effects at very early stages of product development. For example, the 
Ames test, an in vitro method, uses bacteria to determine if a compound may cause 
mutations. It may not be a perfect predictor for genotoxic carcinogens, but if a 
compound causes mutations do you really do want to invest significant resources in 
its development if you have alternatives that do not cause such effects? 
Wageningen University | 9 
At BASF, we have developed a yeast based assay which detects compounds with 
receptor-mediated endocrine effects (Kolle et al. 2010). With current EU legislation 
indicating that compounds showing endocrine effect may not be suitable for 
registration, why run the risk investing in such a compound if you have alternatives? 
And the fact is: early in development industry usually has alternatives. So, knowing 
the toxicological hazard at an early stage helps to select those compounds which cause 
the least harm and have the best chance of passing the regulatory tests. In vitro tests 
help tremendously in this selection process. I can say with certainty that this type of 
early screening with in vitro tests has reduced animal testing far more than the in vitro 
tests which now can be used as complete regulatory alternatives to in vivo testing. 
Finally, it is often mentioned that alternative methods are less expensive than 
animal testing. Unfortunately, this is only partly true. Let me give you two extreme 
examples: The aforementioned yeast assay to determine endocrine effects is 
approximately 7 times less expensive than the in vivo equivalents, (the Hersberger 
and Uterotrophic assays) and avoids the use of 120 animals per compound! 
However, the in vitro alternatives to skin and eye irritation testing that discriminate 
between severe irritants, irritants and non-irritants are 2 – 3 times more expensive 
than the animal test using rabbits. I am very glad that we can now avoid this in vivo 
test, but from a purely financial point of view, the in vitro studies were a step back 
rather than a leap forward. Therefore, the conclusion of the economics of alternative 
methods is: it depends (see: www.estiv.org/docs/Report ESTIV2012.pdf)
 
So how do you develop alternative methods? One way to do this is to look at 
correlations between tests. I will give a few examples: We test for acute toxicity in 
rats, daphnia (water fleas) and fish. If we compare the outcomes of such studies for a 
set of compounds, there is absolutely no correlation between the acute toxicities seen 
in rats and those found in fish or daphnia (see figure 4).
Figure 4. Absence of a correlation between acute toxicity in rats and daphnia
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There is, however, a correlation between the two aquatic organisms. It may not be 
perfect, but as daphnia are not more similar to fish than rats are, it does indicate that 
the environment apparently plays an important role. If we now take one further step 
towards an alternative method and consider the use of fish eggs, we can determine a 
correlation coefficient of R2 = 0.83, a rather good correlation, between the acute 
toxicity endpoints in fish and fish eggs (see figure 5).
Figure 5. Fish eggs are a useful model to predict acute toxicity (lethality) in fish
This correlation can be further increased by taking into account some physico-
chemical properties. As a result, fish eggs have become one of the most important 
alternative methods for reducing animal testing. Why? Toxicity studies are not only 
performed for chemical development, but also used to monitor environmental 
quality. Because of fish eggs, many thousands of fish are not used in water quality 
studies, in particular determinations of the quality of the effluent at waste water 
treatment plants.
Before I continue to show you how we try to address the development of alternative 
methods to replace more complex toxic effects, let me pour you some water in this 
good alternative wine.. Over the last few years we have seen good progress in the 
regulatory acceptance of 3R methods. We have new methods with OECD guideline 
status in which skin and eye irritation testing, formerly performed in rabbits, can be 
replaced by in vitro methods. However, approximately 15 years passed between the 
invention of the method and its regulatory acceptance a very long innovation time. 
Fortunately, the pace of regulatory acceptance of 3R methods is gaining momentum 
and we have seen the innovation time decrease to approximately 7 - 8 years. Last 
year, the OECD guideline 443 – the extended one generation study - was adopted. I 
take pride both in having been a member of the larger International Life Science 
Institute (ILSI) team which helped with the scope of this new study, and in having 
performed and published the first validation study with this guideline (Schneider et 
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al. 2011, Fegert et al. 2012). This study is an excellent example of reduction through 
refinement! The extended one generation study uses up to 1,000 (!) animals less than 
the original 2-generation study, while maintaining sensitivity. Within the context of 
REACH, the European chemical legislation, this new protocol can contribute more to 
reduced animal testing than sum of all other alternative methods currently available. 
But sometimes we are too optimistic concerning the contribution of alternative 
methods. For many years, cytotoxicity studies have been used as guidance to select 
the starting dose for the acute oral toxicity tests, normally the first in vivo study to be 
performed. We have evaluated the contribution of the cytotoxicity test to the correct 
dose selection in comparison to expert opinion and to a fixed dose procedure. It 
turned out that expert judgment outperformed the other two options, but that even a 
fixed dose as a starting point was better than relying on the cytotoxicity test (Schrage 
et al 2011). In my opinion, the reason for this failure is because a post-validation 
evaluation of test method performance is only rarely implemented, even though the 
data are (freely) available. We prefer to look for new horizons rather than looking 
back on the quality of the ships that we have built. Again, let me be clear, this does 
not only relate to in vitro studies, the absence of post validation exercises is also a 
problem in animal studies. For a decade, industry has been required by the USA 
environmental protection agency (EPA) to do developmental neurotoxicity studies, 
which come with a price tag of 750,000 € and use approximately 1,000 rats. Very few, 
if any, of these studies have resulted in significantly new knowledge that was used in 
the risk assessment process. And there are more animal studies of questionable 
relevance to which we will come later. 
Most of the in vitro studies developed and validated so far have related to relatively 
simple endpoints for which often only a yes / no answer need be given, like skin or 
eye irritation and genotoxicity. How do we tackle more complicated toxicological 
endpoints? Most likely the road to success will be in first describing the so called 
“adverse outcome pathway”, that is understanding the process which causes an 
effect, and then designing a series of in vitro studies that address key steps in this 
pathway. Let me give you a successful example. Skin allergy used to be tested in 
guinea pigs, which received multiple injections with the substance, followed by an 
exposure to the skin and evaluations of skin redness. This study was redesigned to 
now consist of a single application of the test substance to the ears of a mouse and 
then evaluation the immunological response in the lymph nodes of these animals. 
Remember the 3Rs, this is a clear refinement. 
But we can do better than just refinement. Let’s look at the process of skin sensiti- 
zation (see figure 6). Step (1): a chemical needs to penetrate the skin – we have 
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an in vitro study (OECD 428) for this. Step (2): the chemical needs to be able to react 
with proteins in the skin – there a chemical reactivity assay for this (the Direct 
Peptide Reactivity Assay, developed by Proctor & Gamble Company). Step (3): the 
chemical must be able to react with skin cells (the keratinocytes) – Givaudan & BASF 
have developed assays. Step (4): the cells of the immune system in the skin (dendritic 
cells) must be able to recognize the altered proteins and be activated – there are 
different assays to test this effect.
Figure 6. Physiological process of skin sensitization (adverse outcome pathway)
We then evaluated the individual and combined performance of these tests and tried 
to set up a testing strategy that gives the best predictive outcome for skin 
sensitization. We have evaluated more than 50 substances of which the allergenic 
potential in humans and animals has been established (it is a rare case in toxicology 
to have extensive well documented human data). Our data so far indicate that the in 
vitro testing strategy outperforms the animal study in predicting human skin 
allergens. I do remember my own words, we will need to keep track of the 
performance of the strategy (the post-validation evaluation), but at this stage I can 
say that we have found a way to identify skin allergens in vitro, which should reduce 
future need for animal testing (Bauch et al, 2012 ).
One of the most important endpoints in toxicology are those of reproduction and 
developmental toxicity, which include infertility, malformations, and retarded 
development. Not only is this true in terms of the consequences, but also in the 
number of animals necessary to perform tests, as well as the financial resources 
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required for new compound development. Reducing the need to rely on animal 
testing for reproduction and developmental toxicity is the topic of my research work 
here in Wageningen. Reproduction toxicity is a very complicated topic and it would 
be foolish to believe that we can simply replace the animal study by a single in vitro 
method. We will need to carefully evaluate existing methods for their performance 
and applicability domain (the chemical classes or modes of action for which an assay 
has a good predictivity). We will also need to try and break down the processes 
which can cause developmental and reproduction toxicity, in particular malforma-
tions. This will allow us to better understand the mechanisms involved, so that we 
can design in vitro studies following the adverse outcome pathway in a way 
analogous to that previously described for the process of skin sensitization.
First steps have already been made. For a compound to directly interact with the 
fetus it must first pass a barrier, the placenta (like skin allergens first need to 
penetrate the skin). Last year we started here in the toxicology department in 
Wageningen the first tests with an in vitro placenta model to evaluate its accuracy in 
predicting the rate of placental transfer of a range of chemicals. This work has shown 
that the BeWo transwell model is an adequate in vitro model to mimic placental 
transfer of a series of selected model compounds and these data are now described in 
the first paper of my PhD student Hequn Li working on this BASF funded project (Li 
et al, 2013). We are now validating this model with a new set of chemicals for which 
the in vivo placenta transfer data are provided by BASF and the in vitro studies are 
performed here at Wageningen University (see figure 7).
Figure 7. Schema of the BeWo assay for placental transfer
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Two in vitro models to determine embryo toxicity (the induction of malformations) 
are currently being validated experimentally, and a few others are under evaluation. 
I hope that in the course of time we will be able to build a tool box of in vitro assays 
which can be used to assess embryo toxicity. With knowledge about the applicability 
domain of each individual assay, we should be able to set up a testing strategy for 
different compounds, particularly if their modes of action are known. Therefore, one 
of our research strategies is to look at groups of compounds and determine which 
assays are best suited to the generation of information (including data from ‘omics 
sciences) which then can be used for a general approach to the identification of 
embryotoxic compounds. The task of producing a strategy for the in vitro 
measurement of developmental and reproduction toxicity is not a piece of cake and 
will require a significant effort and a little bit of luck.
With the following example, I would like to demonstrate that knowledge of the mode 
of action is important in the development of alternative methods and that this goes 
hand in hand with the design of a testing strategy. Chemicals interacting with the 
hormone system are often referred to as endocrine disruptors. I do not particularly 
like this expression because it suggests massive changes and deregulations, whereas 
in reality some of the endocrine effects are actually quite subtle. The European Union 
has decided on a political level that chemicals demonstrating “endocrine disruption” 
should be more strictly regulated or even banned. Interestingly, there is currently no 
definition of what exactly constitutes endocrine disruption. Given the consequences 
and financial risk involved in developing a new compound and finding out that your 
latest darling is an endocrine disruptor which needs to be abandoned, you can image 
that companies would like to know as soon as possible about potential endocrine 
disruption effects. 
The current focus is on compounds that affect steroid hormones, in particular the 
male and female sex hormones, testosterone and estradiol. There are two specific 
animal studies to address this question, the Hershberger assay (OECD 441) and the 
Uterotrophic assay (OECD 440). Without going into too much detail it can be said that 
there are three main mechanisms which can cause chemicals to have endocrine effects: 
(1) receptor mediated effects (2) effects on hormone synthesis, (3) interference with 
hormone metabolism. I mentioned earlier that for receptor mediated effects there is a 
simple yeast based assay. This has been validated with more than 100 compounds 
with known activity and a predictive outcome of > 90 % (Kolle et al, 2010).
For hormone synthesis there is also an in vitro assay using an adrenal cell line which 
produces steroid hormones. By combining these two systems we are able to detect 
the majority of compounds with endocrine disruption activity (see figure 8). What is 
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lacking is the effect of substances on the metabolism of hormones and, as indicated 
earlier, the kinetics and metabolism of the compound itself. To take these parameters 
into account, we have proposed to use information from one of these ‘omics sciences, 
metabolomics.
Figure 8. In vitro assays for the identification of compounds with endocrine effects
Metabolomics is the analysis of the relatively small molecules (< 2,000 dalton) that are 
natural components of living organsims. We have built up a metabolome database 
using blood samples. The reasons for this are simple: blood is easily accessible by 
relatively non-invasive methods and flows through nearly all organs. The idea is that 
chemically-induced toxicity, as well as diseases, will result in a particular fingerprint 
of metabolome changes in the blood. Identification of specific patterns of change can 
then be associated with a particular mode of action, using reference compounds, 
should also enable us to detect these modes of action in new compounds (van 
Ravenzwaay et al 2007). We have now established a database with the metabolome 
patterns of more than 500 chemicals and their toxicity profiles. Combining the 
metabolome information with the known toxicity of these reference compounds, we 
have established more than 100 specific metabolome patterns that are associated with 
particular toxicological effects or mode of action (van Ravenzwaay et al 2012). 
Among these specific patterns are those toxic consequences of compounds with 
endocrine effects. 
Thus, the two aforementioned in vitro studies for the identification of endocrine 
effects work as an excellent first screen to filter out those compounds that have a 
clear endocrine active profile. For those compounds that are “negative” in these 
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assays (i.e. that do not show in vitro endocrine effects) we move forward in the 
development of a product that one day may go to the market. If all other aspects 
(performance, economics, investment required, ecotoxicological profile) are 
favorable, we proceed with in vivo testing (Kolle et al, 2012).
For an agrochemical this means that we embark on a series of up to 40 different 
toxicological studies necessary for regulatory evaluation and registration as a new 
active ingredient. In one of the first of these studies in rats, we take a small sample of 
blood and perform a metabolome analysis. With this, we are able to identify up to 
100 different modes of action including a number of effects associated with endocrine 
disruption. As we are also now dealing with in vivo studies, we have automatically 
included additional modes of action as well. These modes of action include 
interference with hormone metabolism, for which there is as yet no in vitro test, as 
well as all other aspects of kinetics and test substance metabolism, which are still 
hard to account for in in vitro assays. Since we apply metabolomics in studies which 
are already required by regulatory authorities, we do not have to use any additional 
animals. So what we now have for the identification of endocrine disruptors is an 
effective two tiered approach, an in vitro screen for early detection and an omics 
approach to an in vivo system which refines current testing, resulting in an overall 
reduction in animal testing (see figure 9).
Figure 9. A two-tiered testing strategy for the identification of compounds with endocrine effects
As indicated earlier, up to 40 different toxicological studies may be required for the 
development of new active ingredients. Out of these only a few will eventually be 
needed for compound registration with the authorities. The problem is: at the start of 
the toxicological testing program, we do not know what the critical effects will be. 
Consequently some studies will be highly relevant while others will not contribute to 
the risk assessment of the compound in question. This would seem to be unavoidable, 
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however, taking into account the rather low effi  ciency of this process, it is worthwhile 
to consider whether we can do bett er. And indeed, we can do bett er.
The best and simplest alternative to an animal test is to not do the test at all. Is this 
possible without losing essential information for risk assessment? In a retrospective 
analysis of the regulatory relevance of the agrochemicals study set, both the study 
duration and the relevance of the model species (rats, mice and dogs) was assessed 
(Doe et al, 2006). I would like to highlight one particular fi nding here, and that is the 
use of dogs in this set of studies. Several authors have concluded that the use of dog 
as a non-rodent species provides important information for the risk assessment 
process. For about 30 – 50 % of all investigated agrochemicals (depending on the 
database), 90-day studies in dogs provided a lower no observed adverse eff ect level 
(NOAEL) than comparable studies in rats (Spielman and Gerbracht, 2001). Thus, the 
90-day dog study provides essential information and needs to be performed.
Figure 10. The 12-month dog studies do not provide any additional information necessary
for risk assessment
However, the performance of a 12-month toxicity study in dogs has also been 
required for global regulatory acceptance for the last 30 years. Thus, quite a large 
number of 90-day and 12 month dog studies have been performed, providing an 
extensive database. These data were then used to address the question of whether 
there is any additional value added by a 12 month dog study, over and above that of 
the 90-day study. Spielman and Gerbracht (2001) found no clear diff erence in 
sensitivity between 3-month and 12-month studies. In this report, the distribution of 
the ratios between the lowest observed eff ect levels (LOEL) of the subchronic and 
chronic studies (insecticides, herbicides, fungicides) also did not reveal signifi cant 
diff erences between the outcomes of these studies. Doe et al. (2006) as well as Kobil et 
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al. (2010) evaluated sensitivity based on no adverse effect levels while looking at the 
impact on the regulatory outcome if the 12-month dog study would not have been 
performed. In this endeavor, they examined the lowest no adverse effect level of the 
standard set of 4 systemic toxicity studies (90-day rat, 2-year rat, 90-day dog, 1-year 
dog) and compared the resulting lowest NOAEL from these studies with and 
without consideration of the 12-month dog study. 
 
Using a similar approach, we found that for only two compounds the no adverse 
effect level from 12-month dog study was more than 2-times lower than the 
one obtained from the other studies (see figure 10). For one of these, there were 
confounding factors, which made an evaluation difficult. It was therefore concluded 
that the 12-month dog study does not provide essential data for risk assessment. One 
reason for the lack of increased sensitivity with the longer exposure time in dogs may 
be related to their life expectancy relative to duration of treatment. In rat studies, the 
extension of exposure from 3-months to 1 year (chronic) or 2 years (cancer studies), 
takes the duration of exposure, relative to life expectancy, from 12 % to 50% or even 
100 %. In dogs, the 3-month study is equivalent to about 2% of life expectancy, the 
12-month study not more than 8%. Therefore it is plausible that chronic and old-age 
effects are noted in rat, but not in dog studies (see figure 11).
Figure 11. Study duration as a percentage of the life expectancy of the test species
The good news is that these evaluations and conclusions have found their way into 
the regulatory arena. In the EU the 12-month dog study is not an absolute data 
requirement anymore, and the USA-EPA has also indicated that this study does not 
necessarily need to be performed. However, the world is much larger than the EU and 
USA and we need global acceptance, before a data requirement can be completely 
eliminated. In Brazil the discussion about the 12-month dog study as a regulatory 
requirement has started; we hope that Japan will follow soon. Such retrospective 
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assessment, would increase the efficiency of regulatory testing and reduce the number 
of animals used, and therefore, should become a standard procedure. 
In addition to the elimination of irrelevant studies from the list, we can also focus on 
the right testing strategy in order to reduce animal testing for the development of 
new active ingredients. How can we do that without previous knowledge of a 
compounds toxicological profile? The answer can be found in short-term in vivo 
studies, as well as in a broad set of in vitro assays. Such studies can provide 
significantly more data on different endpoints in toxicology than we get right now by 
simply following a check-box approach. I believe that toxicologists would then be 
able to target subsequent testing to those endpoints which are relevant for the 
compound in question, and consequently waive (i.e. provide a rational for not doing 
a particular study) those studies which do not address the toxicological profile of the 
compound. 
Today the focus of most of the regulatory studies still is phenomenological and 
descriptive rather than trying to understand the toxicological profile of a compound. 
However, times are indeed changing! With development of new in vitro studies (e.g. 
those mentioned for endocrine disruption) and with the increased use of ‘omics 
technologies in toxicology, we are entering a new frontier which is much more 
mechanism-based. It is exactly this understanding of the toxicological profile of a 
compound that is essential for a credible targeted-testing design. Consequently, this 
would require a series of in vitro and short-term in vivo studies which would indicate 
not only the general toxicological profile of a compound, but would also aid in 
understanding which modes of action are playing a toxic role for the compound in 
question. 
For this, it would be necessary to agree on the types of in vitro and short-term in vivo 
studies needed (which could include analysis using ’omics sciences (transcriptomics, 
proteomics, metabolomics), in vitro determination of receptor interaction and a good 
understanding of the kinetics and metabolism of the substance. Toxicity testing could 
then be focused and targeted. Such a tiered and targeted toxicity testing approach 
has been proposed more than 7 years ago by the International Life Science Institute 
(Doe et al. 2006). At that time, however, ‘omics sciences and in vitro assays to 
determine mode of action (or adverse outcome pathways) were far less developed 
then they are now. Understanding this underlying toxicology and using these data as 
the basis for targeted testing should be one of the major tasks of the toxicological 
community. As exemplified by the “toxicology in the 21st century” paradigm of the 
US National Academy of Sciences and the USA-EPA tox-cast program, we are well 
underway in this direction. 
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In conclusion, I am optimistic that we can achieve a reduction in animal testing via a 
multi-layered approach. We should continue to assess the standard study package 
for its regulatory effectiveness and eliminate those studies that are not useful for 
compound registration. We should also continue with the innovation of alternative, 
in vitro methods that can replace animal studies. This should include the 
development and use of in vitro studies to identify modes of action during early 
stages of compound development. Such innovations can also be used to terminate 
development of compounds that do not have a chance of being accepted by 
regulatory authorities. Inclusion of ‘omics approaches in short-term regulatory 
studies can be used to understand mode of action in an in vivo situation; then, an 
understanding of all these modes of action can be combined into a single targeted 
approach for toxicity studies.
With all of this said, what makes work at Wageningen University so attractive to me? 
A good team, a long tradition of doing excellent toxicological work, and a unique 
expertise in the development of so called physiologically based pharmacokinetic 
(PBPK) models has been developed here. These mathematical models are necessary 
for the transformation of an in vitro concentration, usually expressed as µg/ml, into a 
dose that would conventionally be used in an animal study (mg/kg body weight). For 
risk assessors, these conventional values are essential; without them it will be close to 
impossible to replace animal studies used for systemic and reproduction toxicity. 
Jochen Louisse from the toxicology group at Wageningen University has already 
demonstrated that such a PBPK approach is feasible (Louisse et al. 2010). 
With my work here at Wageningen University, I hope to contribute to the 
development of in vitro approaches to developmental toxicity. I my teaching 
assignment I will pay special attention to reproduction toxicity as well as alternative 
methods in general and in particular those related to developmental toxicity. We are 
in the process of designing a second PhD project, which will include a transcriptomic 
approach to developmental toxicity. In this project we want to investigate the effect 
of chemicals on the expression of genes which play a role in embryonic development. 
In addition we will take a look at the contribution of nuclear receptor mediated 
effects. We are digging in deep to better understand, at a molecular level, how 
chemicals can cause developmental toxicity. With this understanding I think that we 
will be able to rationally design alternative methods that will contribute to reliably 
identify developmental toxins. I hope that I will be able to give the students a flavor 
of how the results of basic science can be turned into assays that will have an 
immediate application and impact on chemical- and pharmaceutical-industry. Within 
the scope of this work there are several opportunities to work together with other 
groups at Wageningen University, and I am looking forward to new collaborations.
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The ultimate goal is to completely replace animal studies but this will be a long and 
winding road, with uncertain outcome. I hope that I have been able to give you a 
feeling of what can be achieved now, how animal testing can be reduced and how an 
understanding of toxicological mechanisms is key to the development of new and 
better alternative methods.
Now in closing, I would like to express my gratitude to all of the people that have 
made it possible to help me stand where I stand right now.
I would like to thank Mr. Rector Magnificus for demonstrating confidence in me and 
accepting me as a new Professor at Wageningen UR. I would also like to thank Prof. 
Raul Bino for his trust in me and the stimulating discussions we have already had in 
such a short time. I am particularly grateful to Jan Koeman, for two reasons. Firstly, 
he was my first teacher in toxicology and aroused an interest in the science that has 
shaped a good portion of my life. Secondly, because he sent me off to the Germany 
Cancer Research Institute (Deutsches Krebsforschungszentrum – DKFZ) in 
Heidelberg for a six-month internship. Well, that was nearly 29 years ago and I still 
live in the Palatine region. At the Cancer Research Centre I met Dr. Henk Tennekes, a 
former Ph.D. student of Jan Koeman, my future mentor. He introduced me to the 
mathematical aspects of cancer research and biology. I stayed well beyond the 
intended six months; in the end, I did my Ph.D. research there in collaboration with 
Wageningen UR, and so I too became a Ph.D. student of Jan Koeman. In Heidelberg,
I had the good fortune to be able to work with many German scientists who have 
contributed significantly to the early investigations of the biology and molecular 
aspects of cancer. I am in particular grateful to Prof. Werner Kunz, who received me 
with open arms and helped to find my way in the Institute as well as in Heidelberg. 
Having just finished my experimental work in Heidelberg, I found myself, to my 
own surprise, being offered a job at the toxicology department of BASF, 
Ludwigshafen. My great thanks and appreciation to Prof. Hans-Peter Gelbke, who 
had sufficient faith in me that I would be able to survive in the chemical industry as a 
26 year old, not-quite-yet-Ph.D. scientist. A very special thanks to my first boss at 
BASF, Dr. Volker Schulz, who introduced me to single-engine aviation, one of my 
passions, and who has given me the opportunity to start any introduction of myself 
with the words: “I am a true flying Dutchman”.
The first opportunities to start teaching were given to me by Prof. Gerd Eisenbrand in 
Kaiserslautern and Prof. Rolf Schulte-Hermann in Vienna. With hindsight, I am now 
happy to have seized these. With Prof. Dieter Schrenk, we completed the initial 
courses and turned these into a master’s program in toxicology at the University of 
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Kaiserslautern, receiving official acceptance of this curriculum by the federal German 
state Rheinland-Pfalz.
I am honored to be able to expand my work and teaching in academia here in 
Wageningen, and key to this, without any doubt, is Prof. Rietjens. I first met Ivonne in 
1981, during a course in organic chemistry, then in 1983 in the toxicology department 
where she was doing her Ph.D. research. We met again, only two years ago, when we 
started to discuss the possibility for me to work here at Wageningen University.
When I look back on how the toxicological science has affected me, I suppose that 
there are three scientific fields that I will be associated with. Firstly, the potential 
endocrine effects of chemicals; I serendipitously stumbled into this theme while trying 
to explain a number of observations of a compound that turned out to be an anti-
androgen. Due to the mechanistic toxicology studies we initiated, I met Dr. Leon Earl 
Gray of the US-EPA who continued and expanded this work and eventually set the 
stage for what is now generally referred to as “endocrine disruption”. Secondly, 
alternatives to animal studies; at BASF we have focused our “academic” research over 
the last 10 years on the development of alternative methods. Finally, I have enjoyed 
witnessing the rise of the use of metabolomics in toxicology. I am more than grateful 
to the amazing teams at BASF in Ludwigshafen and my dear colleagues at 
Metanomics in Berlin who have achieved more than I could possibly have hoped for. 
Also very big thanks to all the other colleagues in the Experimental Toxicology and 
Ecology and Product Safety departments at BASF; I am proud to work with all of you.
And now, the van Ravenzwaays in Altrip, Germany: to Claudia and my children 
Kimberly and Valerie. All of you have seen me go to many business meetings and 
congresses over the entire world. Although I like to travel, it was always best to get 
back and see you again. To my young ladies, you brighten up my life simply by just 
being with me. 
Then to Milena, I am so glad that you stepped out of your Colombian world and into 
mine, changing it in your South-American way, adding exotic flavors and lots of salsa.
Finally, I would like to thank Henni, my mother, for all she has given me. I moved to 
Germany the year my father died. Ever since then, she has seen more than her fair 
share of the Dutch and German rail- and motorways on the way to the Palatine 
region where I have been living. Thank you very much for your love and support 
over all these years.
I have said,
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‘Many of the in vitro toxicological studies have not been 
sufficiently validated to determine their applicability domain,  
even less have gained regulatory acceptance. Major advantage  
of in vitro testing today is the early identification of significant 
hazards in compound development and reduced and targeted 
animal testing. Replacing complex animal tests may be achieved 
by a battery of in vitro test addressing the adverse outcome 
pathway in question. Kinetics models are needed to translate  
in vitro results into in vivo values.’
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